Agilent Gets FDA Approval for PD-L1 Test in Ovarian Cancer
Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration...